Rintatolimod

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

Retrieved on: 
星期五, 十二月 2, 2022
NYSE, Immunology, EAP, CFS, Congress, COVID-19, Degenerative disease, Society, Special access program, PSLRA, Erasmus MC, ME/CFS, Research, Cancer, AIM, Therapy, Inspectorate, Patient, Pancreatic cancer, Disease, British Society for Neuroendocrinology, Chronic fatigue syndrome, Rintatolimod, Immune system, Pharmaceutical industry

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.

Key Points: 
  • OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.
  • Smidt - Centre for Human Drug Research, Leiden, the Netherlands
    For more information, please visit the Congress website, here .
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

AIM ImmunoTech Announces Corporate Governance Enhancements

Retrieved on: 
星期三, 十一月 9, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Professional Football Compensation Committee, AIM, AIM ImmunoTech, NYSE, Optimism, U.S. Securities and Exchange Commission, Pancreatic cancer, Committee, ME/CFS, Annual general meeting, Food, Chronic fatigue syndrome, Knowledge, Research, Risk, Erasmus MC, Financial compensation, Association, Board, COVID-19, Degenerative disease, CFS, Special access program, Survival, FOLFIRINOX, American Association, Company, Form 10-K, Independent, Ovarian cancer, Patient, Breast cancer, Immune system, Therapy, Security (finance), Inspectorate, Cisplatin, EAP, FDA, American Association for Cancer Research, Management, Pharmaceutical industry, Rintatolimod, Facebook, Cancer

AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced the following corporate governance enhancements:

Key Points: 
  • AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced the following corporate governance enhancements:
    The Governance and Nominating Committee of the AIM Board of Directors (the Board) has initiated a process to add two directors who bring diversity and additional biotechnology commercialization experience to the Board.
  • The corporate governance enhancements we are announcing today are designed to further strengthen our Board through the addition of new independent directors with in-depth knowledge of biotechnology commercialization and diverse backgrounds, and to further align the Companys leadership with AIMs performance and the best interests of all shareholders.
  • Mitchell continued: Over the past year AIM ImmunoTech has made significant progress achieving multiple clinical and regulatory advances.
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting

Retrieved on: 
星期四, 十一月 3, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Company, AIM, Research, Therapy, Degenerative disease, EAP, Risk, Rintatolimod, Form 10-K, Inspectorate, NYSE, Optimism, Erasmus MC, COVID-19, ME/CFS, CFS, Pancreatic cancer, U.S. Securities and Exchange Commission, Cancer, Immune system, Medi-Cal Access Program, Security (finance), Chronic fatigue syndrome, Patient, Public relations, Pharmaceutical industry, Facebook

AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced that shareholders have re-elected all three of the Companys directors, Stewart L. Appelrouth, Thomas K. Equels and William M. Mitchell, at the Companys Annual Meeting of Shareholders (the Annual Meeting) held today.

Key Points: 
  • AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company) today announced that shareholders have re-elected all three of the Companys directors, Stewart L. Appelrouth, Thomas K. Equels and William M. Mitchell, at the Companys Annual Meeting of Shareholders (the Annual Meeting) held today.
  • AIM issued the following statement:
    We are grateful to our shareholders for their support and engagement.
  • The Company will file the final voting results on a Form 8-K with the Securities and Exchange Commission.
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Retrieved on: 
星期三, 十一月 2, 2022
AIM, Inspectorate, Vaccinia, ME/CFS, Ebola, Pancreatic cancer, Chronic fatigue syndrome, Food and Drug Administration, GLOBE, Research, NYSE, Degenerative disease, COVID-19, Program, Disease, Orphan drug, Special access program, Person, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Immune system, Erasmus MC, EVD, EAP, Safety, Condition, Company, Centers for Disease Control and Prevention timeline, Cancer, FDA, Patient, Food, American, CFS, ACHES, Fever, Smallpox vaccine, CDC, Severe acute respiratory syndrome coronavirus 2, Therapy, AIM ImmunoTech, Diagnosis, Vaccine, Pharmaceutical industry, Rintatolimod

OCALA, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Ampligen® (rintatolimod) for the treatment of Ebola virus disease.

Key Points: 
  • Ampligen is AIMs dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
  • Receiving Orphan Drug Designation for Ampligen for the treatment of Ebola from the FDA is a testament to the depth and breadth of the potential with Ampligen.
  • We continue to be encouraged by the promising results Ampligen has demonstrated to date across a number of indications where there remains significant unmet need.
  • Ebola virus disease (EVD) is a rare but severe, deadly disease causing a multitude of symptoms including fever, gastrointestinal issues, aches, and bruising.1 Previous animal studies yielded positive results utilizing Ampligen in Western Equine Encephalitis Virus, Ebola, Vaccinia Virus (which is used in the manufacture of smallpox vaccine) and SARS-CoV-1.

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Retrieved on: 
星期三, 十月 12, 2022
Method, Lists of diseases, Physician, Solve ME/CFS Initiative, American, Disease, Therapy, PSLRA, Fatigue, IND, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, Solve, AIM, Parallel Walk Test, Long, Knowledge, Private Securities Litigation Reform Act, Food, Immune system, Trial of the century, Company, Doctor of Philosophy, Myalgia, Degenerative disease, CEO, Patent, Safety, GLOBE, PLOS, Clinical trial, Government, Running, FDA, COVID-19, ME/CFS, Cancer, M.E, Pharmaceutical industry, Long COVID, Rintatolimod

AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen.

Key Points: 
  • AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen.
  • Post-COVID-19 Disabling Fatigue, along with other debilitating post-COVID conditions such as Brain Fog, continue to affect tens of millions of people worldwide.
  • The planned Phase 2 study is a two-arm, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of Ampligen in patients experiencing the post-COVID condition of fatigue.
  • Significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment for Long COVID.

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Retrieved on: 
星期三, 十月 12, 2022
Method, Lists of diseases, Physician, Solve ME/CFS Initiative, American, Disease, Therapy, PSLRA, Fatigue, IND, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, Solve, AIM, Parallel Walk Test, Long, Knowledge, Private Securities Litigation Reform Act, Food, Immune system, Trial of the century, Company, Doctor of Philosophy, Myalgia, Degenerative disease, CEO, Patent, Safety, GLOBE, PLOS, Clinical trial, Government, Running, FDA, COVID-19, ME/CFS, Cancer, M.E, Pharmaceutical industry, Long COVID, Rintatolimod

AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen.

Key Points: 
  • AIM has pending patent applications for compositions and methods for treating post-COVID conditions with a composition comprising Ampligen.
  • Post-COVID-19 Disabling Fatigue, along with other debilitating post-COVID conditions such as Brain Fog, continue to affect tens of millions of people worldwide.
  • The planned Phase 2 study is a two-arm, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of Ampligen in patients experiencing the post-COVID condition of fatigue.
  • Significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment for Long COVID.

AIM ImmunoTech to Present at the Virtual Investor Long COVID Event

Retrieved on: 
星期三, 九月 21, 2022
Therapy, AIM, Rintatolimod, COVID-19, NYSE, FDA, American, Company, Expanded access, MS, Patient, Event, Investor relations, Degenerative disease, Research, Lists of diseases, GLOBE, Immune system, Cancer, Disease, Pharmaceutical industry

In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions live during the event.

Key Points: 
  • In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions live during the event.
  • The Company will answer as many questions as possible during the event.
  • A live video webcast of the Virtual Investor Long COVID Event will be available on the Events & Presentations page of the Investor Relations section of the Companys website ( aimimmuno.com ).
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

Retrieved on: 
星期一, 九月 19, 2022
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, AIM ImmunoTech, SIGN, Patient, AND, National Diet of Japan Fukushima Nuclear Accident Independent Investigation Commission, CARD, Leadership, Drug development, California Department of Justice, Food, DATE, THE, Annual general meeting, Vanderbilt University School of Medicine, Company, Liver, Accounting, CKM, DNA, SEC, INTERNET, AIM, NYSE, Ovarian cancer, Association, Cancer, THOMAS, Bring Your Board!!, Board, Pathology, Fatigue, Department, Justice, Erasmus MC, Colorectal cancer, Pancreatic cancer, American Association, OR, Activism, Letter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breast cancer, BOARD, Board of directors, Holding company, Pharmaceutical industry, Medical device, Online gambling, Medical imaging, Management, Rintatolimod, Shareholder, American

The Board of Directors (Board) of AIM ImmunoTech Inc. (NYSE: American AIM) (AIM or the Company), today announced that the Company has filed its Definitive Proxy Statement in connection with AIMs upcoming 2022 Annual Meeting of Stockholders (the Annual Meeting), to be held on November 3, 2022, and has mailed this statement, along with a letter, to shareholders.

Key Points: 
  • The Board of Directors (Board) of AIM ImmunoTech Inc. (NYSE: American AIM) (AIM or the Company), today announced that the Company has filed its Definitive Proxy Statement in connection with AIMs upcoming 2022 Annual Meeting of Stockholders (the Annual Meeting), to be held on November 3, 2022, and has mailed this statement, along with a letter, to shareholders.
  • Thank you for your investment and your trust in AIM ImmunoTech (AIM or the Company).
  • The Board has unanimously determined that Mr. Jorgls director nominations did not comply with AIMs bylaws and are invalid.
  • THE BOARD RECOMMENDS A VOTE FOR ALL OF OUR BOARDS NOMINEES (STEWART L. APPELROUTH, THOMAS K. EQUELS AND WILLIAM M. MITCHELL)ON PROPOSAL 1 USING THE ENCLOSED WHITE PROXY CARD.

AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
星期三, 九月 7, 2022
COVID-19, Lists of diseases, NYSE, Research, AIM, Disease, Rintatolimod, Degenerative disease, GLOBE, Conference, Immune system, Therapy, Cancer, Investor, American, Event, Vaccine

Chief Executive Officer of AIM, will present at the virtual H.C. Wainwright 24 th Annual Global Investment Conference being held in New York, N.Y., and virtually, September 12-14, 2022.

Key Points: 
  • Chief Executive Officer of AIM, will present at the virtual H.C. Wainwright 24 th Annual Global Investment Conference being held in New York, N.Y., and virtually, September 12-14, 2022.
  • In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
  • For more information about the conference, please visit the conference website .
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

Retrieved on: 
星期二, 九月 6, 2022
COVID-19, Lists of diseases, NYSE, Roswell Park Comprehensive Cancer Center, Research, AIM, Oncogenomics, Disease, Board, Rintatolimod, Pharmacology, Degenerative disease, GLOBE, Company, Therapy, Immune system, Cancer, American, Pharmaceutical industry

Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022.

Key Points: 
  • Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022.
  • In addition to managements presentations, the Company is proud to announce its sponsorship of the event.
  • Presentations will take place at the Cancer Genetics & Pharmacology Building at the Roswell Park Comprehensive Center.
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.